Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Analysts Say ‘Load Up’ on These 2 Nuclear Power Stocks — Here’s Why

View original at finance.yahoo.com
Analysts Say ‘Load Up’ on These 2 Nuclear Power Stocks — Here’s Why The widespread push toward energy sector decarbonization is well underway, and usually turns investor attention toward wind or solar power…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Near-term catalysts include hyperscaler deal by year-end, Calpine accretion, costs coming down on Crane restart, and uprate opportunities moving above 2 GW fleetwide

    80% confidence
  • Terrestrial is attractively valued relative to its nuclear reactor technology peer group, with market cap ~37% below peer median despite strong regulatory progress and commercial engagement

    80% confidence
  • CEG remains best Independent Power Producer idea with ideal mix and scale of assets, leadership position on nuclear contracting, with FERC/PJM regulatory clarity creating opportunities

    80% confidence
  • Overweight rating on Constellation Energy with $460 price target

    80% confidence
  • Every week there are announcements of new companies or governments expanding nuclear capacity or revisiting prior stances on nuclear as the world seeks ways to expand, accelerate or incentivize new nuclear capacity

    80% confidence
  • Outperform rating on Terrestrial Energy with $15 price target

    80% confidence
  • Terrestrial maintains sizable cash balance representing ~27% of market cap vs peer median of 14%, providing meaningful liquidity runway to advance licensing, engineering and business development

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com